Laboratory Investigation of Myeloproliferative Neoplasms (MPNs)

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

(2015) J. D. Milosevic Feenstra et al.   BLOOD

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

(2015) X. Cabagnols et al.   BLOOD

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

(2015) T Barbui et al.   Blood Cancer Journal

Discriminating between essential thrombocythemia and masked polycythemia vera inJAK2mutated patients

(2014) Tiziano Barbui et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report

(2014) José M Raya et al.   JOURNAL OF CLINICAL PATHOLOGY

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

(2014) P Guglielmelli et al.   LEUKEMIA

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

(2014) A Tefferi et al.   LEUKEMIA

Age-related mutations associated with clonal hematopoietic expansion and malignancies

(2014) Mingchao Xie et al.   NATURE MEDICINE

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Masked polycythemia vera diagnosed according to WHO and BCSH classification

(2013) Tiziano Barbui et al.   AMERICAN JOURNAL OF HEMATOLOGY

Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis

(2013) R. T. Silver et al.   BLOOD

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

(2013) Srdan Verstovsek et al.   CANCER

Rethinking the diagnostic criteria of polycythemia vera

(2013) T Barbui et al.   LEUKEMIA

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update

(2013) Hans Michael Kvasnicka   Current Hematologic Malignancy Reports

How I treat polycythemia vera

(2012) F. Passamonti   BLOOD

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome

(2012) T. Barbui et al.   BLOOD

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations

(2012) Anthony J. Bench et al.   BRITISH JOURNAL OF HAEMATOLOGY

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

(2012) Lambert Busque et al.   NATURE GENETICS

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients

(2011) A. Tefferi et al.   BLOOD

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

(2011) J. Thiele et al.   BLOOD

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

(2011) F. Passamonti et al.   BLOOD

Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia

(2011) Argirios E. Tsantes et al.   BLOOD COAGULATION & FIBRINOLYSIS

Pitfalls in molecular diagnosis in haemato-oncology

(2011) J. Mason et al.   JOURNAL OF CLINICAL PATHOLOGY

Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count

(2010) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Guideline for investigation and management of adults and children presenting with a thrombocytosis

(2010) Claire N. Harrison et al.   BRITISH JOURNAL OF HAEMATOLOGY

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of Exon 12 Mutations in the JAK2 Gene

(2010) Todd S. Laughlin et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

(2010) D Caramazza et al.   LEUKEMIA

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

(2010) Richard T. Silver et al.   LEUKEMIA RESEARCH

Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients

(2010) Valerie Ugo et al.   PLoS One

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis

(2009) K. Hussein et al.   BLOOD

JAK2V617F allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis

(2009) Kais Hussein et al.   EXPERIMENTAL HEMATOLOGY

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera

(2009) S. Schnittger et al.   HAEMATOLOGICA

Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia

(2009) Juergen Thiele et al.   JOURNAL OF CLINICAL ONCOLOGY

Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy

(2009) Peter J. Campbell et al.   JOURNAL OF CLINICAL ONCOLOGY

High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations

(2009) Inmaculada Rapado et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

(2009) Ayalew Tefferi et al.   Nature Reviews Clinical Oncology

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

(2008) P. A. Beer et al.   BLOOD

Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis

(2008) A. V. Jones et al.   HAEMATOLOGICA

ICSH guidelines for the standardization of bone marrow specimens and reports

(2008) S.-H. LEE et al.   International Journal of Laboratory Hematology

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA